Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head and neck cancer, after revealing promising phase 3 trial results.
Novartis has announced it would not raise drug prices in the US this year, while Merck & Co announced huge cuts in the price of its hepatitis drug following pressure from president Trum